Sponsored Content by Corning Life SciencesNov 16 2022Reviewed by Olivia Frost The ultimate decision between adherent and suspension cell culture platforms must frequently be made by therapy developers to scale production to satisfy demand. Based on the cell type, timing, required output, available production space and labor, cost, and other considerations, each has advantages and disadvantages.
Corning field applications experts, sales representatives, and scientific support professionals collect intelligence and discuss customer productivity concerns and bottlenecks. To create viable solutions, they then draw on Corning’s decades of materials science experience and profound understanding of cell biology and behavior.
It is intended to provide important surface area intensification and high-yield bioproduction capacity in a platform that scales from benchtop process development to commercial production. Customers’ feedback throughout alpha and beta testing resulted in crucial design modifications, resulting in a totally closed system featuring an integrated controller, media conditioning vessel, bioreactor vessel, and sensors.